LSL Web-Exclusive Content

31. How To Reduce Costs And Risk For Cell & Gene Therapy Facilities 8/7/2023

    When it comes to cell and gene therapy (CGT) facilities, how will you save costs in construction, commissioning/qualification/validation, and ongoing operations? It all has to do with risk. Let's take a closer look at why considering risk the best way to reduce the costs of a CGT facility.

32. How Supporting The STEM Pipeline Can Help With Workforce Shortages 8/2/2023

    The persistent reality is that not all students have equal access to STEM education. Where our education system is hampered by systemic barriers, our corporate institutions can step up — by leveraging their resources and relationships to support the building blocks of STEM education.

33. Bridging The Gap: Separating The Facts From Medical Misinformation 8/1/2023

    Misinformation about medical matters is hardly a recent phenomenon. Still, the instant and universal reach of social media and the internet has made it a potentially more damaging problem, as illustrated by the pandemic.

34. 6 Tips For Collaboration In Rare Disease Clinical Research 7/28/2023

    What does it mean to truly collaborate within industry in clinical research, particularly as it relates to advancing cures for rare disease? Baylor University Medical Center Program Director for the Department of Internal Medicine Ankit Mehta, MD, shares six ways clinical research professionals can better work alongside each other.

35. Decentralization: It's More Than You Think 7/26/2023

    Decentralization is not only a breakthrough in trial design but also in the larger field of scientific research and represents a paradigm shift in the digital world. It drives patient empowerment, trial accessibility, and new fundraising models. 

36. An Overview Of FDA Draft Guidance On "Manufacturing Changes And Comparability For Human CGT Products" 7/24/2023

    This article provides a detailed overview of The U.S. Food and Drug Administration's highly anticipated draft guidance to the industry that addresses “Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products.”

37. Full-Service Or Specialty CRO: Which One Is Right For You? 7/24/2023

    The pool of capable CRO organizations from which to choose is vast, so when it comes time to select whom you should outsource, there is no one-size-fits-all answer or "best" option. Ask yourself these five questions when considering whether to hire a full-service CRO, specialty CRO, or a combination of both.

38. Save Time And Money By Using AI To Compare CRO Proposals 7/21/2023

    Old way versus new way. Audrey Rossow, director of clinical operations at Precirix, examines tried and true methods of finding outsource partners with the up-and-coming AI technologies that aim to make that process quicker, easier, and possibly cheaper.

39. Why Do So Many Alzheimer's Clinical Trials Fail? 7/19/2023

    Over the past 20 years, 98% of Alzheimer’s disease treatment clinical trials have failed. But why? INmune Bio CEO and Chief Medical Officer RJ Tesi, MD explores what he says are the three main reasons why so few AD clinical trials succeed.

40. June 2023 — CDMO Opportunities And Threats Report 7/18/2023

    Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.